Adjuvant Nivolumab Approved in Europe for Melanoma

July 31, 2018 – The European Commission has approved nivolumab as an adjuvant treatment for adult patients with completely resected melanoma with lymph node involvement or metastatic disease, regardless of BRAF mutation status. The approval was based on findings from the randomized phase III CheckMate-238 trial, in which the recurrence-free survival (RFS) rate at 18 months with nivolumab was 66.4% (95% CI, 61.8%-70.6%) compared with 52.7% … (leggi tutto)